- AbbVie’s Risankizumab for Crohn’s disease receives positive opinion from UK MHRA
- Chinese COVID-19 vaccines are not so effective against COVID-19 and not suitable as booster shot.
- Shanghai COVID outbreaking: over 500K people infected and 87 deaths
- More than 70% of COVID-19 patients still have sequelae after one year
- First cases of mink-to-human transmission of COVID-19 in United States
- Biogen withdraws marketing application of Alzheimer’s drug Aduhelm from EU
UK investigating allergic reactions of Pfizer/BioNTech Vaccines
UK investigating allergic reactions of Pfizer/BioNTech Vaccines. Pfizer and BioNTech are worried about the theft of vaccine information; on the other hand, although the vaccine has already been obtained in the UK market, allergies after vaccination have been reported. According to the Associated Press, British regulators said on the 9th that they have received two reports from Pfizer and BioNTech, which are allergic reactions that may be related to the COVID-19 vaccine. The vaccinators of allergic reactions are from the British Coronavirus Vaccination Program.
June Raine, the head of the British medical regulator, revealed the news when testifying to a committee of Parliament. She said that researchers are still investigating these two reports of allergic reactions, and clinical trials of the vaccine did not initially find that this reaction would become a potential problem. Currently, regulators are calling for people with a history of severe allergic reactions not to get the vaccine.
Just before this news, a data released on the 8th showed that in the trial involving 44,000 volunteers conducted by Pfizer, none of the participants had “have a history and/or response to vaccine-related serious adverse reactions. Any component of the research intervention produces a severe allergic reaction.”
Pfizer and BioNTech announced in early November that phase 3 study data showed that their vaccine is more than 90% effective in preventing participants who have not previously been infected with COVID-19. At that time, the trial enrolled more than 43,000 subjects, 42% of whom came from different ages, genders and ethnic backgrounds. At that time, there were no serious safety hazards reported. In addition, the Data Monitoring Committee did not report any serious safety issues related to vaccines. After the first or second vaccination, only serious adverse events with a frequency greater than or equal to 2% occurred, including fatigue (3.8%) and headache (2%). A review of the unblinded reactivity data from the final analysis showed that the subjects were well tolerated by the vaccine, and most of the adverse reactions caused would disappear on their own shortly after the vaccination process.
According to current forecasts, Pfizer and BioNTech will be able to produce up to 50 million doses of vaccines worldwide by the end of this year. It is expected that this number will increase to 1.3 billion doses by the end of 2021. At that time, the occurrence of allergic reactions may not stop there. For example, the use of a large number of vaccinators is the real world to further verify the efficacy and safety of the vaccine.